ClinicalTrials.gg
CompletedNCT01776840Updated Jul 8, 2025Results posted

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

A Phase 3 interventional study of Bendamustine and Rituximab in Mantle Cell Lymphoma, sponsored by Janssen Research & Development, LLC. Completed at 201 sites in 28 countries. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2025-07-08.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
523
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 45 studies testing ibrutinib in Lymphoma, Mantle-Cell — 2 open to participants now, 16 under way, 2 of them phase 3. ibrutinib · Lymphoma, Mantle-Cell.

Enrollment
3rd of 45
523 · median 39
Started
2013
with 3 others
Phase 3
6 of 45
1 open now
Registered
7th of 45
by date
Lead sponsor
6 of 45
Janssen Research & Development, LLC

Among the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, this one is the 3rd largest by enrollment, is one of 4 that started in 2013, is one of 6 in phase 3, and was the 7th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

2 of the 45 studies testing ibrutinib in Lymphoma, Mantle-Cell are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ibrutinib

ibrutinib: first FDA approval 2013 (IMBRUVICA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing ibrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ibrutinib given in combination with bendamustine and rituximab in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.

Read the detailed description

This is a randomized (individuals assigned to study treatment by chance), double blind (neither physician nor participant knows the treatment that the participant receives), placebo (an inactive substance that is compared with a drug to test whether the drug has a real effect in a clinical trial)-controlled study to compare the efficacy and safety of ibrutinib given in combination with bendamustine and rituximab (BR) with BR alone in participants newly diagnosed with mantle cell lymphoma (MCL) who are 65 years of age or older. Approximately 520 participants will be randomly assigned in a 1:1 ratio and stratified by simplified Mantle Cell Lymphoma International Prognostic Index (MIPI) score (low risk [0-3] versus intermediate risk [4-5] versus high risk [6-11]). The treatment phase will extend from randomization until discontinuation of all study treatment or the clinical cutoff for the end of study. A cycle is defined as 28 days. All participants will receive open-label (identity of assigned study drug will be known) BR background therapy for a maximum of 6 cycles; participants with a complete response or partial response will continue to receive open-label background therapy with rituximab maintenance every second cycle for a maximum of 12 additional doses. In addition to the background therapy, all participants will receive blinded study drug (ibrutinib or placebo). Participants randomized to treatment Arm A will receive placebo capsules and participants randomized to treatment Arm B will receive ibrutinib capsules. Study drug will be administered daily and continuously until disease progression, unacceptable toxicity, or study end. Participants with stable disease after initial chemoimmunotherapy (BR+ibrutinib/placebo) should continue treatment with ibrutinib/placebo until disease progression, unacceptable toxicity, or study end. Participants with progressive disease must discontinue all study treatment. For participants who discontinue background therapy and do not have progressive disease, treatment with study drug will continue until disease progression or unacceptable toxicity or the clinical cutoff for the final analysis of progression-free survival (PFS). Participants receiving BR, rituximab, or ibrutinib at the clinical cutoff for the final analysis of PFS will continue open-label treatment until disease progression or unacceptable toxicity. Placebo will be stopped when the study is unblinded for the clinical cutoff for the final analysis of PFS. The posttreatment follow-up phase will begin once a participant discontinues bendamustine and rituximab and study drug. Participants who discontinue for reasons other than disease progression must continue to have disease evaluations as outlined in the protocol. Participants who discontinue due to disease progression will be followed for survival and subsequent anti-MCL therapy. The posttreatment follow-up phase will continue until death, lost to follow up, consent withdrawal, or study end, whichever occurs first. Four clinical cutoffs are planned. The first 3 clinical cutoffs will occur when approximately 134, 180, and 265 PFS events have been observed, respectively. The interim analyses and the final analysis of PFS will take place at these 3 clinical cutoffs, respectively; participant treatment assignment will be unblinded and placebo treatment will be stopped at the clinical cutoff for the final analysis of PFS. Treatment unblinding and stopping of placebo treatment could occur before the planned final analysis of PFS if recommended by the independent Data Monitoring Committee (DMC) after an interim analysis. The last cutoff will occur at the end of study, when 60% of the randomized participants have died or the Sponsor terminates the study, whichever comes first. Efficacy assessments will be conducted in accordance with the Revised Response Criteria for Malignant Lymphoma. Safety will be monitored throughout the study and summarized. Blood samples will be drawn for assessment of pharmacokinetic parameters. Blood and bone marrow will be collected for assessment of minimal residual disease and biomarker studies.

03

Conditions studied

  • Mantle Cell Lymphoma

Keywords

  • Mantle cell lymphoma
  • Ibrutinib
  • Bruton's tyrosine kinase inhibitor
  • Bendamustine hydrochloride
  • Rituximab
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of mantle cell lymphoma (MCL) reviewed and approved by central laboratory: diagnosis must include morphology and expression of either cyclin D1 in association with other relevant markers (eg, CD19, CD20, PAX5 and CD5) or evidence of t(11;14) as assessed by cytogenetics, fluorescent in situ hybridization (FISH), or polymerase chain reaction (PCR)
  • Clinical Stage II, III, or IV by Ann Arbor Classification
  • At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma
  • No prior therapies for MCL
  • (ECOG) performance status grade 0 or 1
  • Hematology and biochemical laboratory values within protocol-defined limits
  • Agrees to protocol-defined use of effective
  • Negative blood or urine pregnancy test at screening

Exclusion criteria

Exclusion Criteria:

  • Major surgery within 4 weeks of random assignment
  • Known central nervous system lymphoma
  • Diagnosed or treated for other than MCL, except: malignancy treated with curative intent and with no known active disease present for >=3 years before random assignment; adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease; adequately treated cervical carcinoma in situ without evidence of disease
  • Patients for whom the goal of therapy is tumor debulking prior to stem cell transplant
  • History of stroke or intracranial hemorrhage within 6 months prior to random assignment
  • Requires anticoagulation with warfarin or equivalent vitamin K antagonists
  • Requires treatment with strong inhibitors
  • cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of Screening, or any Class 3 (moderate) or Class 4 (severe) cardiac disease as defined by the Functional Classification
  • Vaccinated with live, attenuated vaccines within 4 weeks of random assignment
  • Known history of (HIV) or active virus or active virus infection or any uncontrolled active systemic infection requiring intravenous antibiotics
  • Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib capsules, or put the study outcomes at undue risk
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
523 participants (actual)

Study arms

  • Placebo comparator
    Treatment Arm A

    Drug: Bendamustine · Drug: Rituximab · Drug: Placebo

  • Experimental
    Treatment Arm B

    Drug: Bendamustine · Drug: Rituximab · Drug: Ibrutinib

Interventions

  • 90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6

  • 375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses

  • 560 mg (4 x 140 mg capsules) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end

  • DrugPlacebo

    4 capsules administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or the final analysis of progression-free survival

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS)

    Progression-free survival (PFS) was defined as the interval between the date of randomization to the date of disease progression (PD) or relapse from complete response (CR) or death, whichever was first reported. Disease assessments were based on the 2007 Revised Response Criteria for Malignant Lymphoma. PD was defined as any new lesion or increase by 50 percent (%) of previously involved sites from nadir (PD criteria: Appearance of new nodal lesion 1.5 centimeters \[cm\] in any axis, 50% increase in sum of product of diameters \[SPD\] of greater than \[\>\] 1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis).

    Time frame: Up to 97 months

Secondary outcomes

  1. Overall Survival

    Overall survival was defined as the time from the date of randomization to the date of the participant's death. Kaplan-Meier estimate was used.

    Time frame: From randomization (Day -3) up to 121 months

  2. Complete Response Rate

    Complete response (CR) rate was defined as the percentage of participants who achieve CR (based on investigator assessment) on or prior to the initiation of subsequent anticancer therapy. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if positron emission tomography (PET) negative; regression to normal size on computed tomography (CT); spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy.

    Time frame: Up to 97 months

  3. Time-to-Next Treatment

    Time-to-next treatment was measured from the date of randomization to the start date of any anti-mantle cell lymphoma (anti-MCL) treatment subsequent to the study treatment.

    Time frame: Up to 97 months

  4. Percentage of Participants With Overall Response

    Percentage of participants with overall response was defined as the portion of participants who achieved CR or PR. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. Criteria for PR: greater than or equal to (\>=) 50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions.

    Time frame: Up to 97 months

  5. Minimal Residual Disease (MRD)-Negative Response Rate

    Minimal residual disease negative rate was defined as the percentage of participants with a best overall response of CR with MRD-negative disease status (that is, \<5 mantle cell lymphoma \[MCL\] cell per 10,000 leukocytes for detection using the MRD assay), as assessed by flow cytometry of a bone marrow and/or peripheral blood sample.

    Time frame: Up to 97 months

  6. Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Questionnaire

    Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline, death, or a missing assessment due to being "too ill", whichever occurred first. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score was the total of reverse scores, ranged 0 to 60. Higher scores indicated a better quality of life.

    Time frame: Up to 97 months

  7. Duration of Response (DoR)

    Duration of Response (DoR) was defined as the interval between the date of initial documentation of a response including PR and the date of first documented evidence of PD or death

    Time frame: Up to 97 months

  8. Duration of Complete Response (DoCR)

    Duration of complete response (DoCR) was defined as the interval between the date of initial documentation of a CR and the date of first documented evidence of PD or death whichever occurs first.

    Time frame: Up to 97 months

  9. Time to Response

    Time to response was defined as the interval between the date of randomization and the date of initial documentation of a response.

    Time frame: Up to 97 months

  10. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. Treatment-emergent adverse events were defined as adverse events with onset or worsening on or after date of first dose of study treatment up to and including 30 days after date of last dose of study medication, or the initiation of subsequent anticancer therapy, whichever is earlier.

    Time frame: Placebo + BR (Treatment A): From first dose of study treatment (Day 1) up to 100.1 months; Ibrutinib + BR (Treatment B): From first dose of study treatment (Day 1) up to 117.2 months

  11. Oral Plasma Clearance (CL/F) of Ibrutinib

    CL/F was defined as apparent total systemic clearance of ibrutinib after extravascular administration. Cl/F of Ibrutinib was determined using population pharmacokinetics (PopPK modeling).

    Time frame: Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2

  12. Oral Volume of Distribution at Steady State of Ibrutinib

    Oral volume of distribution at steady state of ibrutinib was determined using PopPK modeling.

    Time frame: Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2

  13. Area Under the Concentration Curve of Ibrutinib During 24 Hours After Dosing at Steady State

    Area under the concentration curve of ibrutinib during 24 hours after dosing at steady state was determined using PopPK modeling.

    Time frame: Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2

  14. Minimum Observed Plasma Concentration of Ibrutinib

    Minimum observed plasma concentration of ibrutinib was determined using PopPK modeling.

    Time frame: Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2

  15. Maximum Observed Plasma Concentration of Ibrutinib

    Maximum observed plasma concentration of ibrutinib was determined using PopPK modeling.

    Time frame: Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2

07

Results

Posted Jul 26, 2022

Participant flow

Participant flow — Overall Study
MilestonePlacebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Started262261
Safety analysis set (treated)260259
Completed129119
Not completed133142
Withdrew: Lost to follow-up127
Withdrew: Withdrawal by subject3248
Withdrew: Sponsor decision8987

Outcome measures

PrimaryProgression-free Survival (PFS)

Progression-free survival (PFS) was defined as the interval between the date of randomization to the date of disease progression (PD) or relapse from complete response (CR) or death, whichever was first reported. Disease assessments were based on the 2007 Revised Response Criteria for Malignant Lymphoma. PD was defined as any new lesion or increase by 50 percent (%) of previously involved sites from nadir (PD criteria: Appearance of new nodal lesion 1.5 centimeters \[cm\] in any axis, 50% increase in sum of product of diameters \[SPD\] of greater than \[\>\] 1 node or 50% increase in longest diameter of previously identified node 1 cm in short axis).

Time frame:
Up to 97 months
Reported as:
Median · months
Progression-free Survival (PFS)
monthsPlacebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Progression-free Survival (PFS)52.9 (43.7 to 71.0)80.6 (61.9 to NA)
Statistical analysis
  • Placebo + Bendamustine and Rituximab (BR) (Treatment A) vs Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B) · Log Rank · p = 0.011 · Hazard ratio (hr): 0.75 · 95% CI 0.59 to 0.96
SecondaryOverall Survival

Overall survival was defined as the time from the date of randomization to the date of the participant's death. Kaplan-Meier estimate was used.

Time frame:
From randomization (Day -3) up to 121 months
Reported as:
Median · months
Overall Survival
monthsPlacebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Overall Survival95.9 (86.1 to 115.3)104.3 (81.1 to NA)
SecondaryComplete Response Rate

Complete response (CR) rate was defined as the percentage of participants who achieve CR (based on investigator assessment) on or prior to the initiation of subsequent anticancer therapy. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if positron emission tomography (PET) negative; regression to normal size on computed tomography (CT); spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy.

Time frame:
Up to 97 months
Reported as:
Number · percentage of participants
Complete Response Rate
percentage of participantsPlacebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Complete Response Rate57.665.5
SecondaryTime-to-Next Treatment

Time-to-next treatment was measured from the date of randomization to the start date of any anti-mantle cell lymphoma (anti-MCL) treatment subsequent to the study treatment.

Time frame:
Up to 97 months
Reported as:
Median · months
Time-to-Next Treatment
monthsPlacebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Time-to-Next Treatment92.0 (71.5 to NA)NA (NA to NA)
SecondaryPercentage of Participants With Overall Response

Percentage of participants with overall response was defined as the portion of participants who achieved CR or PR. Criteria for CR: disappearance of all evidence of disease; mass of any size permitted if PET negative; regression to normal size on CT; spleen and liver: not palpable, nodules disappeared; bone marrow: infiltrate cleared on repeat biopsy. Criteria for PR: greater than or equal to (\>=) 50% decrease in sum of the diameter of all target lesions compared with baseline, in absence of new lesions or unequivocal progression of non-target lesions.

Time frame:
Up to 97 months
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Response
percentage of participantsPlacebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Percentage of Participants With Overall Response88.589.7
SecondaryMinimal Residual Disease (MRD)-Negative Response Rate

Minimal residual disease negative rate was defined as the percentage of participants with a best overall response of CR with MRD-negative disease status (that is, \<5 mantle cell lymphoma \[MCL\] cell per 10,000 leukocytes for detection using the MRD assay), as assessed by flow cytometry of a bone marrow and/or peripheral blood sample.

Time frame:
Up to 97 months
Reported as:
Number · percentage of participants
Minimal Residual Disease (MRD)-Negative Response Rate
percentage of participantsPlacebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Minimal Residual Disease (MRD)-Negative Response Rate56.562.1
SecondaryTime to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Questionnaire

Time to worsening in the Lymphoma subscale of the FACT-Lym, defined as the interval from the date of randomization to the start date of worsening of participant symptoms. Worsening was defined by a 5-point decrease from baseline, death, or a missing assessment due to being "too ill", whichever occurred first. FACT-Lym Lymphoma subscale contains 15 questions, scores from 0 to 4 for each question (higher the worse). Lymphoma subscale score was the total of reverse scores, ranged 0 to 60. Higher scores indicated a better quality of life.

Time frame:
Up to 97 months
Reported as:
Median · months
Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Questionnaire
monthsPlacebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Time to Worsening (TTW) in the Lymphoma (Lym) Subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Questionnaire22.2 (9.3 to 34.0)17.4 (8.3 to 27.6)
SecondaryDuration of Response (DoR)

Duration of Response (DoR) was defined as the interval between the date of initial documentation of a response including PR and the date of first documented evidence of PD or death

Time frame:
Up to 97 months
Reported as:
Median · months
Duration of Response (DoR)
monthsPlacebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Duration of Response (DoR)63.5 (47 to 76.9)81 (64.2 to NA)
SecondaryDuration of Complete Response (DoCR)

Duration of complete response (DoCR) was defined as the interval between the date of initial documentation of a CR and the date of first documented evidence of PD or death whichever occurs first.

Time frame:
Up to 97 months
Reported as:
Median · months
Duration of Complete Response (DoCR)
monthsPlacebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Duration of Complete Response (DoCR)78.1 (65.6 to NA)NA (81.7 to NA)
SecondaryTime to Response

Time to response was defined as the interval between the date of randomization and the date of initial documentation of a response.

Time frame:
Up to 97 months
Reported as:
Median · months
Time to Response
monthsPlacebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Time to Response2.79 (1.9 to 11.2)2.79 (2.1 to 10.1)
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the intervention. Treatment-emergent adverse events were defined as adverse events with onset or worsening on or after date of first dose of study treatment up to and including 30 days after date of last dose of study medication, or the initiation of subsequent anticancer therapy, whichever is earlier.

Time frame:
Placebo + BR (Treatment A): From first dose of study treatment (Day 1) up to 100.1 months; Ibrutinib + BR (Treatment B): From first dose of study treatment (Day 1) up to 117.2 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsPlacebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Number of Participants With Treatment-emergent Adverse Events (TEAEs)257259
SecondaryOral Plasma Clearance (CL/F) of Ibrutinib

CL/F was defined as apparent total systemic clearance of ibrutinib after extravascular administration. Cl/F of Ibrutinib was determined using population pharmacokinetics (PopPK modeling).

Time frame:
Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2
Reported as:
Mean · liter per hour (L/h)
Oral Plasma Clearance (CL/F) of Ibrutinib
liter per hour (L/h)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Oral Plasma Clearance (CL/F) of Ibrutinib1123 ± 4.83
SecondaryOral Volume of Distribution at Steady State of Ibrutinib

Oral volume of distribution at steady state of ibrutinib was determined using PopPK modeling.

Time frame:
Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2
Reported as:
Mean · liter
Oral Volume of Distribution at Steady State of Ibrutinib
literIbrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Oral Volume of Distribution at Steady State of Ibrutinib7286 ± 7.87
SecondaryArea Under the Concentration Curve of Ibrutinib During 24 Hours After Dosing at Steady State

Area under the concentration curve of ibrutinib during 24 hours after dosing at steady state was determined using PopPK modeling.

Time frame:
Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2
Reported as:
Mean · nanogram*hour per milliliter (ng*h/mL)
Area Under the Concentration Curve of Ibrutinib During 24 Hours After Dosing at Steady State
nanogram*hour per milliliter (ng*h/mL)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Area Under the Concentration Curve of Ibrutinib During 24 Hours After Dosing at Steady State425 ± 267
SecondaryMinimum Observed Plasma Concentration of Ibrutinib

Minimum observed plasma concentration of ibrutinib was determined using PopPK modeling.

Time frame:
Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2
Reported as:
Mean · nanograms per milliliter (ng/mL)
Minimum Observed Plasma Concentration of Ibrutinib
nanograms per milliliter (ng/mL)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Minimum Observed Plasma Concentration of Ibrutinib3.90 ± 2.64
SecondaryMaximum Observed Plasma Concentration of Ibrutinib

Maximum observed plasma concentration of ibrutinib was determined using PopPK modeling.

Time frame:
Pre-dose on Day 2 of Cycles 1, 2 and 3; and 1, 2 and 4 hours post-dose on Day 2 of Cycles 1 and 2
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration of Ibrutinib
ng/mLIbrutinib + Bendamustine and Rituximab (BR) (Treatment B)
Maximum Observed Plasma Concentration of Ibrutinib74.5 ± 48.3

Adverse events

Collected over All-cause mortality: From randomization (Day -3) up to 121 months; SAEs and Non SAEs: Placebo + BR (Treatment A): From first dose of study treatment (Day 1) up to 100.1 months; Ibrutinib + BR (Treatment B): From first dose of study treatment (Day 1) up to 117.2 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Bendamustine and Rituximab (BR) (Treatment A)129/262 (49.2%)157/260 (60.4%)255/260 (98.1%)
Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)120/261 (46%)201/259 (77.6%)256/259 (98.8%)
Most frequent serious events
Showing 10 of 365
Most frequent serious events
EventPlacebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
PneumoniaInfections and infestations35/26058/259
PyrexiaGeneral disorders14/26019/259
Febrile NeutropeniaBlood and lymphatic system disorders9/26016/259
Atrial FibrillationCardiac disorders4/26014/259
SepsisInfections and infestations6/26010/259
CellulitisInfections and infestations3/2609/259
DiarrhoeaGastrointestinal disorders2/2608/259
Covid-19 PneumoniaInfections and infestations2/2608/259
Acute Kidney InjuryRenal and urinary disorders2/2608/259
BronchitisInfections and infestations4/2607/259
Most frequent other events
Showing 10 of 93
Most frequent other events
EventPlacebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)
DiarrhoeaGastrointestinal disorders96/260119/259
NeutropeniaBlood and lymphatic system disorders104/260109/259
NauseaGastrointestinal disorders107/260109/259
RashSkin and subcutaneous tissue disorders57/26095/259
PyrexiaGeneral disorders76/26088/259
CoughRespiratory, thoracic and mediastinal disorders85/26078/259
AnaemiaBlood and lymphatic system disorders60/26083/259
FatigueGeneral disorders77/26079/259
Upper Respiratory Tract InfectionInfections and infestations69/26070/259
ConstipationGastrointestinal disorders66/26052/259

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)Total
Mean71.7 ± 5.271.8 ± 5.0471.7 ± 5.12
Age, Customized
Age, Customized(Participants)Placebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)Total
70 years and over154162316
< 70 years10899207
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)Total
Female7683159
Male186178364
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)Total
Hispanic or Latino171835
Not Hispanic or Latino234232466
Unknown or Not Reported111122
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Placebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)Total
American Indian or Alaska Native303
Asian424789
Black or African American123
Native Hawaiian or Other Pacific Islander000
White206199405
More than one race112
Unknown or Not Reported91019
Other022
Region of Enrollment
Region of Enrollment(Participants)Placebo + Bendamustine and Rituximab (BR) (Treatment A)Ibrutinib + Bendamustine and Rituximab (BR) (Treatment B)Total
ARGENTINA044
AUSTRALIA121931
BELGIUM10515
BRAZIL101121
CANADA7411
CHINA263157
CZECH REPUBLIC8715
FRANCE13821
GERMANY538
GREECE347
HUNGARY5510
IRELAND022
ISRAEL9514
ITALY131326
JAPAN4711
MEXICO213
NETHERLANDS358
POLAND171835
RUSSIAN FEDERATION121527
SLOVAKIA213
SOUTH KOREA6612
SPAIN71320
SWEDEN9918
TAIWAN426
TURKEY6814
UKRAINE5611
UNITED KINGDOM161430
UNITED STATES483583
08

Study locations

201 sites
  • Tucson, Arizona, United States
  • Burbank, California, United States
  • La Jolla, California, United States
  • Stanford, California, United States
  • Denver, Colorado, United States
  • New Haven, Connecticut, United States
  • Stamford, Connecticut, United States
  • Chicago, Illinois, United States
  • Maywood, Illinois, United States
  • Niles, Illinois, United States
  • Springfield, Illinois, United States
  • Goshen, Indiana, United States
  • Iowa City, Iowa, United States
  • Sioux City, Iowa, United States
  • Topeka, Kansas, United States
  • Westwood, Kansas, United States
  • Lexington, Kentucky, United States
  • Louisville, Kentucky, United States
  • Metairie, Louisiana, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • Jefferson City, Missouri, United States
  • Lincoln, Nebraska, United States
  • Hackensack, New Jersey, United States
  • New Brunswick, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Albany, New York, United States
  • Hawthorne, New York, United States
  • New York, New York, United States
  • Durham, North Carolina, United States
  • Greenville, North Carolina, United States
  • Bismarck, North Dakota, United States
  • Fargo, North Dakota, United States
  • Eugene, Oregon, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Greenville, South Carolina, United States
  • Watertown, South Dakota, United States
  • Nashville, Tennessee, United States
  • Houston, Texas, United States
  • San Antonio, Texas, United States
  • Burlington, Vermont, United States
  • Spokane, Washington, United States
  • Vancouver, Washington, United States
  • Buenos Aires, Argentina
  • Córdoba, Argentina
  • La Capital, Argentina
  • Paraná, Argentina
  • Adelaide, Australia
  • Auchenflower, Australia
  • Box Hill, Australia
  • Concord, Australia
  • Douglas, Australia
  • Gosford, Australia
  • Hobart, Australia
  • Prahran, Australia
  • Antwerp, Belgium
  • Bruges, Belgium
  • Brussels, Belgium
  • Ghent, Belgium
  • Leuven, Belgium
  • Wilrijk, Belgium
  • Yvoir, Belgium
  • Barretos, Brazil
  • Goiânia, Brazil
  • Porto Alegre, Brazil
  • Ribeirão Preto, Brazil
  • Rio de Janeiro, Brazil
  • São Paulo, Brazil
  • Edmonton, Alberta, Canada
  • Vancouver, British Columbia, Canada
  • Hamilton, Ontario, Canada
  • Ottawa, Ontario, Canada
  • Montreal, Quebec, Canada
  • Beijing, China
  • Chengdu, China
  • Guangzhou, China
  • Hangzhou, China
  • Shanghai, China
  • Tianjin, China
  • Brno, Czechia
  • Hradec Králové, Czechia
  • Prague, Czechia
  • Créteil, France
  • F-75 730 Paris Cedex 15, France
  • Grenoble, France
  • Nantes, France
  • Paris, France
  • Pessac, France
  • Tours, France
  • Berlin, Germany
  • Heidelberg, Germany
  • Jena, Germany
  • Mainz, Germany
  • München, Germany
  • TÿBINGEN, Germany
  • Ulm, Germany
  • Villingen-Schwenningen, Germany
  • Athens, Greece
  • Athens Attica, Greece

Showing the first 100 of 201 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Wang ML, Jurczak W, Jerkeman M, Trotman J, Zinzani PL, Belada D, Boccomini C, Flinn IW, Giri P, Goy A, Hamlin PA, Hermine O, Hernandez-Rivas JA, Hong X, Kim SJ, Lewis D, Mishima Y, Ozcan M, Perini GF, Pocock C, Song Y, Spurgeon SE, Storring JM, Walewski J, Zhu J, Qin R, Henninger T, Deshpande S, Howes A, Le Gouill S, Dreyling M; SHINE Investigators. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022 Jun 30;386(26):2482-2494. doi: 10.1056/NEJMoa2201817. Epub 2022 Jun 3. PubMed 35657079 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2013 to primary completion in Jun 2021, 97 months.

Results were first posted in Jul 2022, 1 year after primary completion.

Of 27 phase 3 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 68. This study's 97 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 24, 2013
First posted
Jan 28, 2013
StartActual
May 16, 2013
Primary completionActual
Jun 30, 2021
CompletionActual
Jun 24, 2024
Results first posted
Jul 26, 2022
Last update
Jul 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01776840
Collaborators
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Jan 28, 2013
Start date
May 16, 2013
Primary completion
Jun 30, 2021
Completion
Jun 24, 2024
Results posted
Jul 26, 2022
Last update
Jul 8, 2025

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibrutinib

Start the discussion